ImmuPharma PLC (IMM) — Tangible Net Worth Ratio
ImmuPharma PLC (IMM) has a Tangible Net Worth Ratio of 98.5% as of June 2025. This metric is calculated by deducting intangible assets (GBX5.00K) from net assets (GBX336.70K) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore ImmuPharma PLC equity growth rate to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
ImmuPharma PLC Tangible Net Worth Ratio (2004–2023)
This chart shows how ImmuPharma PLC's Tangible Net Worth Ratio has changed across 21 annual periods from 2004 to 2023. As of June 2025, the ratio stands at 98.5%, reflecting net assets of GBX336.70K with intangible assets of GBX5.00K GBX. For live market cap and overall valuation, see ImmuPharma PLC stock valuation.
Annual Tangible Net Worth Ratio for ImmuPharma PLC (2004–2023)
The table below presents the year-by-year Tangible Net Worth Ratio for ImmuPharma PLC from 2004 to 2023, covering 21 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. Explore IMM capital expenditure intensity to see what proportion of operating cash flow is directed to capital expenditures.
| Year | Tangible NW Ratio | Net Assets (GBX) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2023 | 57.6% | GBX1.06 Million | GBX447.57K | GBX2.72 Million | ▼ -23.6 pp |
| 2022 | 81.2% | GBX2.52 Million | GBX473.89K | GBX3.97 Million | ▼ -8.0 pp |
| 2021 | 89.2% | GBX4.41 Million | GBX477.55K | GBX6.00 Million | ▼ -5.8 pp |
| 2020 | 95.0% | GBX9.65 Million | GBX484.04K | GBX10.92 Million | ▲ +4.1 pp |
| 2019 | 90.9% | GBX5.27 Million | GBX478.96K | GBX5.80 Million | ▼ -2.8 pp |
| 2018 | 93.7% | GBX7.62 Million | GBX483.04K | GBX8.66 Million | ▲ +7.2 pp |
| 2017 | 86.5% | GBX3.57 Million | GBX482.27K | GBX5.02 Million | ▼ -4.3 pp |
| 2016 | 90.8% | GBX5.55 Million | GBX511.09K | GBX6.71 Million | ▲ +21.7 pp |
| 2015 | 69.1% | GBX1.69 Million | GBX522.46K | GBX3.21 Million | ▼ -21.1 pp |
| 2014 | 90.2% | GBX5.71 Million | GBX560.54K | GBX7.07 Million | ▲ +1.3 pp |
| 2013 | 88.9% | GBX5.40 Million | GBX602.07K | GBX7.21 Million | ▼ -3.7 pp |
| 2012 | 92.5% | GBX8.42 Million | GBX627.68K | GBX10.51 Million | ▼ -2.1 pp |
| 2011 | 94.7% | GBX12.51 Million | GBX666.00K | GBX14.28 Million | ▼ -0.9 pp |
| 2010 | 95.6% | GBX15.97 Million | GBX705.00K | GBX17.55 Million | ▼ -0.3 pp |
| 2009 | 95.9% | GBX18.08 Million | GBX747.00K | GBX24.64 Million | ▲ +3.1 pp |
| 2008 | 92.8% | GBX11.24 Million | GBX809.00K | GBX13.40 Million | ▲ +17.6 pp |
| 2007 | 75.2% | GBX3.05 Million | GBX755.00K | GBX4.10 Million | ▼ -12.0 pp |
| 2006 | 87.3% | GBX5.89 Million | GBX749.00K | GBX7.33 Million | ▲ +17.8 pp |
| 2006 | 69.4% | GBX2.50 Million | GBX765.00K | GBX3.63 Million | ▼ -30.6 pp |
| 2005 | 100.0% | GBX993.00K | GBX0.00 | GBX1.01 Million | ▲ +0.0 pp |
| 2004 | 100.0% | GBX978.00K | GBX0.00 | GBX980.00K | — |